top of page

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

blonca9
Apr 1
1 min read

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach.

Note: IDEA Pharma and Candel have a business relationship (as discussed).

Recent Posts

See All

Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial readouts scheduled in DMD and DM1 over the next year

Sunrise Group, which has designed a mandibular sensor for at-home diagnosis of sleep apnea, recently raised $29M to expand its digital sleep clinic that patients can access remotely

Oxford, UK based OMass Therapeutics, experts in the use of mass spectrometry in drug development, recently landed a $20M up front licensing deal with Roche on one of its preclinical candidates for IBD

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Learn more about Klein Hersh